Poly‑D,L‑lactic acid (PDLLA) scalp microinjection protocol with optional light microneedling priming for non‑scarring alopecia: A prospective pilot case series
Olena Sydorchuk , Jino Kim , Jong Keun Song , Nilesh H. Pawar , Isabella Rosellini , Han Earl Lee , Massimo Vitale , Kyu-Ho Yi
{"title":"Poly‑D,L‑lactic acid (PDLLA) scalp microinjection protocol with optional light microneedling priming for non‑scarring alopecia: A prospective pilot case series","authors":"Olena Sydorchuk , Jino Kim , Jong Keun Song , Nilesh H. Pawar , Isabella Rosellini , Han Earl Lee , Massimo Vitale , Kyu-Ho Yi","doi":"10.1016/j.jpra.2026.01.030","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>PDLLA demonstrates angiogenic and regenerative properties that may support hair regrowth by enhancing perifollicular perfusion. Objective: To evaluate clinical improvement after PDLLA scalp microinjection in 20 patients using standardized photography and Global Aesthetic Improvement Scale (GAIS) rated by two independent physicians.</div></div><div><h3>Methods</h3><div>Twenty adults with non scarring alopecia received PDLLA scalp microinjections at baseline and week 4 (optional booster at week 8). Optional light microneedling priming (0.5–0.8 mm) was performed immediately before PDLLA injection in 14/20 patients to facilitate distribution. Primary endpoint was physician rated GAIS at week 12; secondary endpoints included patient GAIS and safety. Images were acquired with fixed camera to scalp distance and lighting.</div></div><div><h3>Results</h3><div>Physician GAIS improved in 90% of patients at week 12 (mean ± SD 3.3 ± 0.6) and was maintained at week 24 (3.1 ± 0.7). Patient reported GAIS was 3.2 ± 0.7 at week 12. No serious adverse events occurred.</div></div><div><h3>Conclusions</h3><div>In this pilot uncontrolled case series, PDLLA scalp microinjections were associated with physician‑rated GAIS improvement over 12–24 weeks with favorable short‑term tolerability. Given the subjective endpoint, the absence of a comparator arm, and optional microneedling priming in a subset of patients, the findings are preliminary and require confirmation in controlled studies with objective trichologic measurements and longer follow‑up.</div></div>","PeriodicalId":37996,"journal":{"name":"JPRAS Open","volume":"48 ","pages":"Pages 914-923"},"PeriodicalIF":1.8000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JPRAS Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352587826000380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
PDLLA demonstrates angiogenic and regenerative properties that may support hair regrowth by enhancing perifollicular perfusion. Objective: To evaluate clinical improvement after PDLLA scalp microinjection in 20 patients using standardized photography and Global Aesthetic Improvement Scale (GAIS) rated by two independent physicians.
Methods
Twenty adults with non scarring alopecia received PDLLA scalp microinjections at baseline and week 4 (optional booster at week 8). Optional light microneedling priming (0.5–0.8 mm) was performed immediately before PDLLA injection in 14/20 patients to facilitate distribution. Primary endpoint was physician rated GAIS at week 12; secondary endpoints included patient GAIS and safety. Images were acquired with fixed camera to scalp distance and lighting.
Results
Physician GAIS improved in 90% of patients at week 12 (mean ± SD 3.3 ± 0.6) and was maintained at week 24 (3.1 ± 0.7). Patient reported GAIS was 3.2 ± 0.7 at week 12. No serious adverse events occurred.
Conclusions
In this pilot uncontrolled case series, PDLLA scalp microinjections were associated with physician‑rated GAIS improvement over 12–24 weeks with favorable short‑term tolerability. Given the subjective endpoint, the absence of a comparator arm, and optional microneedling priming in a subset of patients, the findings are preliminary and require confirmation in controlled studies with objective trichologic measurements and longer follow‑up.
期刊介绍:
JPRAS Open is an international, open access journal dedicated to publishing case reports, short communications, and full-length articles. JPRAS Open will provide the most current source of information and references in plastic, reconstructive & aesthetic surgery. The Journal is based on the continued need to improve surgical care by providing highlights in general reconstructive surgery; cleft lip, palate and craniofacial surgery; head and neck surgery; skin cancer; breast surgery; hand surgery; lower limb trauma; burns; and aesthetic surgery. The Journal will provide authors with fast publication times.